EIK1001 Clinical Trials
3 recruitingDrug
Phase 23Phase 32
Showing 1–3 of 3 trials
Recruiting
Phase 2Phase 3
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Stage 4 NSCLCNon Small Cell Lung Cancer (Squamous or Non Squamous)
Eikon Therapeutics750 enrolled10 locationsNCT07365319
Recruiting
Phase 2Phase 3
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Advanced Melanoma
Eikon Therapeutics740 enrolled107 locationsNCT06697301
Recruiting
Phase 2
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
NSCLC
Eikon Therapeutics70 enrolled39 locationsNCT06246110